TORONTO, Feb. 12 /CNW/ - Theralase Technologies Inc. (TSX-V: TLT), a
developer, manufacturer and distributor of therapeutic medical laser systems,
today announced positive research and development results in the destruction
of individual cancer cell lines. This research is aimed at combining patented
photodynamic compounds (PDCs), under exclusive worldwide licence to Theralase,
with the Company's patented bio-feedback laser technology for the selective
destruction of cancers, bacteria, viruses and fat cells.
